Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

December 4, 2008

Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate

September 2, 2008

Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008

July 30, 2008

Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA)

June 24, 2008

Anavex Further Strengthens Board of Directors

June 3, 2008

Anavex Announces Appointment of Oncology Specialist to Board of Directors

May 21, 2008

Low density of sigma-1 receptors in early Alzheimer’s disease.

April 10, 2008

ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity

March 10, 2008

Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008

January 22, 2008

Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

December 28, 2007

Anavex Strengthens Board of Directors

December 17, 2007

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

December 11, 2007
1
23456789101112131415161718192021222324252627282930
…3132333435…
36373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top